JP2007524613A5 - - Google Patents

Download PDF

Info

Publication number
JP2007524613A5
JP2007524613A5 JP2006517417A JP2006517417A JP2007524613A5 JP 2007524613 A5 JP2007524613 A5 JP 2007524613A5 JP 2006517417 A JP2006517417 A JP 2006517417A JP 2006517417 A JP2006517417 A JP 2006517417A JP 2007524613 A5 JP2007524613 A5 JP 2007524613A5
Authority
JP
Japan
Prior art keywords
antigen
cancer
agent
melanoma
renal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006517417A
Other languages
English (en)
Japanese (ja)
Other versions
JP5283335B2 (ja
JP2007524613A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/019571 external-priority patent/WO2004112825A2/en
Publication of JP2007524613A publication Critical patent/JP2007524613A/ja
Publication of JP2007524613A5 publication Critical patent/JP2007524613A5/ja
Application granted granted Critical
Publication of JP5283335B2 publication Critical patent/JP5283335B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006517417A 2003-06-17 2004-06-17 各種癌の治療を目的とした腫瘍関連抗原の組合せ Expired - Fee Related JP5283335B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47955403P 2003-06-17 2003-06-17
US60/479,554 2003-06-17
PCT/US2004/019571 WO2004112825A2 (en) 2003-06-17 2004-06-17 Combinations of tumor-associated antigens for the treatment of various types of cancers

Publications (3)

Publication Number Publication Date
JP2007524613A JP2007524613A (ja) 2007-08-30
JP2007524613A5 true JP2007524613A5 (enExample) 2010-05-13
JP5283335B2 JP5283335B2 (ja) 2013-09-04

Family

ID=33539189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006517417A Expired - Fee Related JP5283335B2 (ja) 2003-06-17 2004-06-17 各種癌の治療を目的とした腫瘍関連抗原の組合せ

Country Status (7)

Country Link
US (2) US20050118186A1 (enExample)
EP (2) EP1633387B1 (enExample)
JP (1) JP5283335B2 (enExample)
AT (1) ATE546153T1 (enExample)
AU (2) AU2004249254B2 (enExample)
CA (1) CA2529056C (enExample)
WO (1) WO2004112825A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
WO2006009920A2 (en) 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
JP2008503494A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 診断方法を治療方法と統合することによる免疫療法の効力改善
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060153844A1 (en) * 2004-12-29 2006-07-13 Thomas Kundig Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
KR101294290B1 (ko) * 2004-12-29 2013-08-07 맨카인드 코포레이션 예방 또는 치료를 위해 제ｉ류 주조직 적합성복합체〔ｍｈｃ〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법
PL1833506T3 (pl) 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
NZ564360A (en) * 2005-06-17 2011-03-31 Mannkind Corp Immunogenic product comprising a nucleic acid capable of expressing a PRAME epitope and a PSMA epitope and a peptide composition
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
US20080014211A1 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes
MX2009008620A (es) * 2007-02-15 2009-10-22 Mannkind Corp Un metodo para mejorar la respuesta de celulas t.
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
MX2012004721A (es) 2009-10-23 2012-06-25 Mannkind Corp Inmunoterapia de cancer y metodo de tratamiento.
CN102336821B (zh) * 2011-08-11 2014-10-15 北京永泰免疫应用科技有限公司 Melan-A表位肽及其在预防和/或治疗肿瘤中的用途
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
WO2013052108A2 (en) * 2011-10-03 2013-04-11 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2016011386A1 (en) * 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
US9827308B2 (en) * 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
CR20170507A (es) 2015-04-13 2018-02-13 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
CA2982543A1 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0668777T3 (da) * 1992-11-05 2007-02-19 Sloan Kettering Inst Cancer Prostataspecifikt membran-antigen
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5512437A (en) * 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US5512444A (en) * 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
US5763165A (en) * 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5837476A (en) * 1995-03-03 1998-11-17 Ludwig Institute Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
US6025191A (en) * 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5856136A (en) * 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US5888751A (en) * 1997-07-15 1999-03-30 Ludwig Institute For Cancer Research Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6387888B1 (en) * 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
ATE513913T1 (de) * 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US6531015B1 (en) * 2000-05-30 2003-03-11 Associated Hygienic Products System and process for making a disposable absorbent garment such as a diaper training pants
US7252824B2 (en) 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2002086071A2 (en) * 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US7076244B2 (en) 2001-07-23 2006-07-11 Research In Motion Limited System and method for pushing information to a mobile device
US20050019341A1 (en) * 2001-10-30 2005-01-27 Kyogo Itoh Tumor antigen
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
CA2496888A1 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer

Similar Documents

Publication Publication Date Title
JP2007524613A5 (enExample)
Grant et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin
Batich et al. Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma
Harrop et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
Gavilondo et al. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial
Choi et al. EGFRvIII‐targeted vaccination therapy of malignant glioma
Creemers et al. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol
Gulley Therapeutic vaccines: the ultimate personalized therapy?
JP2012021028A5 (enExample)
Melief “License to kill” reflects joint action of CD4 and CD8 T cells
Tian et al. Nanomedicine for combination urologic cancer immunotherapy
Ahmed et al. The rise of the TROP2-targeting agents in NSCLC: new options on the horizon
Rong et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine
Calvani et al. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs
CN107249587B (zh) 用于治疗乳腺癌的抗组胺药
Mohsen et al. In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma
Madan et al. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer
Mahon et al. Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer
Wang et al. rWTC‐MBTA vaccine induces potent adaptive immune responses against glioblastomas via dynamic activation of dendritic cells
Chong et al. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer
Cavacini et al. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen
US20190216907A1 (en) Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
Abdul‐Wahid et al. A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo
Gonzalez Marinello et al. Epidermal growth factor vaccine in non-small-cell lung cancer
Lin et al. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer